Fiche du document
2015
- doi: 10.1007/s11892-015-0669-3
- issn: 1534-4827
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1007/s11892-015-0669-3
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/26395924
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1539-0829
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_E40C429E71273
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
TherapyCiter ce document
A. Daruich et al., « Sustained-release steroids for the treatment of diabetic macular edema. », Serveur académique Lausannois, ID : 10.1007/s11892-015-0669-3
Métriques
Partage / Export
Résumé
Glucocorticoids have been used for decades in the treatment of ocular disorders via topical, periocular, and more recently intravitreal routes. However, their exact mechanisms of action on ocular tissues remain imperfectly understood. Fortunately, two recently approved intravitreal sustained-release drug delivery systems have opened new perspectives for these very potent drugs. To date, among other retinal conditions, their label includes diabetic macular edema, for which a long-lasting therapeutic effect has been demonstrated both morphologically and functionally in several randomized clinical trials. The rate of ocular complications of intravitreal sustained-release steroids, mainly cataract formation and intraocular pressure elevation, is higher than with anti-vascular endothelial growth factor agents. Yet, a better understanding of the mechanisms underlying these adverse effects and the search for the minimal efficient dose should help optimize their therapeutic window.